Board of Directors

Russell G. Greig, Ph.D. worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008 as well as on the GlaxoSmithKline corporate executive team. Currently, Dr. Greig serves as Chairman of Merus and MedEye Solutions in the Netherlands, eTheRNA in Belgium, Sanifit in Spain and Horama in France He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States), Novagali in France (acquired by Santen, Japan) and Syntaxin in the United Kingdom (acquired by Ipsen, France), as well as board member of TiGenix in Belgium (acquired by Takeda, Japan).

Mr. Dambach has over two decades of experience in the life sciences and financial services sectors and currently serves as Vice President and Treasurer of Biogen Inc., where he is responsible for capital allocation, cash and liquidity management, financial and operational risk management, and general corporate stewardship. Prior to joining Biogen, Mr. Dambach served as Assistant Treasurer with Thermo Fisher Scientific Inc., where he implemented the treasury integration strategy between Thermo Election and Fisher Scientific and was responsible for capital markets activities and the development of strategic balance sheet management strategies, including the redemption of long-term debt and share repurchases. Earlier in his career, Mr. Dambach held several senior executive level roles within the financial services sector, including FleetBoston Financial Corporation and BankBoston. Mr. Dambach received his B.S. in Business Administration from the University of New Hampshire and received his M.B.A. from Boston University. Mr. Dambach holds the Chartered Financial Analyst (CFA) certification.

Mr. Marks is a senior global life sciences executive for clinical stage to commercial businesses with extensive experience in public company board management. Mr. Marks most recently served as Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary, and as Senior Advisor, with Amarin Corporation plc, where he was responsible for leading the legal, compliance, and legal operations functions acting as a strategic advisor to the management and the Board. Prior to joining Amarin, Mr. Marks served as Chief Legal Officer and Head of Corporate Development for TerrAscend Corp, where he was responsible for the management of legal, compliance and corporate development functions. Mr. Marks was also Chief Legal Officer and Corporate Secretary for InflaRX, N.V. Earlier in his career, Mr. Marks held senior legal and compliance roles with Bausch Health Companies, including as SVP, Head Legal, Branded Rx and Global Litigation & Government Investigations, at Alcon Laboratories, including as Head Legal, North America and Global Litigation and Government Investigations, and for Stryker Corporation in both the United States and in Europe. He received his A.B in History from the University of Chicago and received his J.D. (with honors) from the George Washington University Law School.

Alan Moses, M.D., was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston. He was appointed Professor of Medicine at Harvard Medical School. Over the course of 14 years at Novo Nordisk, Dr. Moses served in multiple roles, rising to the position of Senior Vice President and Global Chief Medical Officer. During his tenure there, Dr. Moses provided medical support to regulatory filings for the approval of 11 successful Novo Nordisk products. Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.

Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.

Ms. Sullivan most recently served as Chief Financial Officer for Compass Therapeutics, LLC. Prior to Compass, Ms. Sullivan served as the Senior Vice President of Finance for Biogen, Inc., where she spearheaded Biogen’s Financial Planning & Analysis, Corporate Tax, and Corporate Finance groups, which includes ownership of long-range planning, capital allocation projects and the financial aspects of Mergers & Acquisitions/Business Development. Prior to that, Ms. Sullivan was the Vice President of Tax for Biogen, Vice President Tax for EMD Serono and the Vice President of Tax North America at Merck KgaA. Ms. Sullivan serves also on the Boards of resTORbio and Solid Biosciences.